Chi-Ping Day, Ph.D.
Dr. Day's research focuses on the development of transgenic and preclinical models of recurrent and metastatic diseases, and identification of therapeutic targets of metastatic melanoma.
Dr. Day's expertise is in cancer modeling and translation of preclinical testing to clinics, focusing on immunotherapies and its combinations with other treatment. His researches emphasize the modeling as an approach to map the complex system through a process of continuous improvement. He also have many years of experience in building the infrastructure of research, facilitating the efficiency, proficiency, and productivity of a lab under appropriate budget control.
Inventions 1. Lentiviral vectors for long term in vivo expression of dual fluorescence/luminescence reporters. (2011) Inventors: Dominic Esposito, Chi-Ping Day, and Glenn Merlino. NIH Employee Invention Report Reference No. E‐132‐2011. 2. A bioimaging marker‐tolerant mouse allowing consistent tumor labeling and monitoring in an immunocompetent mouse model. (2010) Inventors: Chi-Ping Day and Glenn Merlino. NIH Employee Invention Report Reference No. E‐173‐2010.
- Laboratory Investigation. (Accepted): 2017. [ Journal Article ]
- Cancer Research. 76(20): AACR 5921-5925, 2016. [ Journal Article ]
- Cell. 163 (1): 39-53, 2015. [ Journal Article ]
"Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts..PLoS One. 9 (11): e109956., 2014. [ Journal Article ]
Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin.Int. J. Cancer. 130: 190-9, 2012. [ Journal Article ]
Dr. Chi-Ping Day received his BS diploma in chemistry from National Cheng-Kung University, Tainan, Taiwan in 1992 and MS diploma in biochemistry from National Yang-Ming University, Taipei, Taiwan in 1996. He then joined the Graduate School of Biomedical Sciences at the University of Texas Health Science Center at Houston and M. D. Anderson Cancer Center, where he received his Ph.D. in 2005 for his work on the development of breast cancer-specific gene therapy system. In October 2005, he joined the laboratory of Dr. Merlino as a visiting fellow to receive his post-doctoral training, then became Staff Scientist in 2012.